Oruka Therapeutics, Inc.
ORKA
$41.75
$0.000.00%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.79M | 5.12M | 4.34M | 5.16M | 6.00M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 34.43M | 34.11M | 28.43M | 25.09M | 37.46M |
| Operating Income | -34.43M | -34.11M | -28.43M | -25.09M | -37.46M |
| Income Before Tax | -29.58M | -30.28M | -24.57M | -21.00M | -33.39M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -29.58M | -30.28M | -24.57M | -21.00M | -33.39M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -29.58M | -30.28M | -24.57M | -21.00M | -33.39M |
| EBIT | -34.43M | -34.11M | -28.43M | -25.09M | -37.46M |
| EBITDA | -34.40M | -34.09M | -28.41M | -25.07M | -37.44M |
| EPS Basic | -0.45 | -0.55 | -0.46 | -0.40 | -0.54 |
| Normalized Basic EPS | -0.34 | -0.43 | -0.36 | -0.31 | -0.46 |
| EPS Diluted | -0.45 | -0.55 | -0.46 | -0.40 | -0.54 |
| Normalized Diluted EPS | -0.34 | -0.43 | -0.36 | -0.31 | -0.46 |
| Average Basic Shares Outstanding | 54.59M | 44.07M | 42.10M | 41.68M | 43.86M |
| Average Diluted Shares Outstanding | 54.59M | 44.07M | 42.10M | 41.68M | 43.86M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |